肿瘤细胞与线粒体双靶向Bcl-2蛋白抑制剂载体系统

基本信息
批准号:81271686
项目类别:面上项目
资助金额:70.00
负责人:吴道澄
学科分类:
依托单位:西安交通大学
批准年份:2012
结题年份:2016
起止时间:2013-01-01 - 2016-12-31
项目状态: 已结题
项目参与者:徐梁,杜建强,甘震海,高巍,潘兴华,李科,巨建辉,曾鋆,白雁
关键词:
线粒体肿瘤靶向Bcl2蛋白抑制剂
结项摘要

The tumor chemtherapy strategy is the key problem for the design of anti-tumor drug delivery system. In this project, with the selection and characteristics of Bcl-2 protein inhibition of (-) gossypol, tumor cells targeting of hyaluronic acid, as well as the mitochondrial targeting of triphenylphosphines (TPP)cation, the dual-targeting drug delivery system to tumor cells and their mitochondrials is prepared as follows: (-) gossypol amino m-PEG nanoparticles are prepared by the encapsulation of (-) gossypol with amino m-PEG using self -assemble method, then triphenylphosphine bromonexanoic acid cations are conjugated to the amino group of the nanoparticles by N-ethyl-N'-3-(dimethylamino)propylcabodiimid(EDC )and N-hydroxysuccinimide(NHS), the dual-targeting drug delivery system will be obtained by encapsulate the shell of hyaluronic acid on the (-) gossypol m-PEG nanoparticles. Their surface and chemical structures can be determined by IR , NMR spectra and so on. Their targeting characteristics for tumor cells and their mitochondrials can be measured by the fluorescent labeling,fluorescence lifetime, mitochondrial membrane potential,FQ-PCR and circular dichroism(CD), respectively. Their antitumor effects will be detected by cell tests in vitro and aminal tests in vivo. This kind of Bcl-2 protein inhabitor delivery system with the chracteristics of tumor cells and their mitochondrials targeting can be both targeted combined to the tumor cells with hyaluronic acid and combined to their mitochondrial membrane with triphenylphosphine cation after they are came into the tumor cells, (-) gossypol can inhibit Bcl-2 proteins more effectively than common gossypol delivery system, thereby obtain optimal inhibition of Bcl-2 proteins and antitumor effects.

肿瘤化疗策略是抗肿瘤药物载体设计的关键。本项目以肿瘤细胞及其线粒体为目标靶点,综合应用左旋棉酚等对Bcl-2蛋白的抑制,透明质酸、三苯基膦阳离子化合物对肿瘤细胞及其线粒体的目标选择和靶向性。将左旋棉酚等用氨基m-PEG自组装包裹形成纳米粒子,通过交联剂EDC和N-羟基琥珀酰亚胺与三苯基膦溴代己酸阳离子的羧基结合形成线粒体靶向纳米粒子。再将PEG修饰的透明质酸包裹在外层制成具有肿瘤细胞及其线粒体双靶向载体系统。红外光谱、核磁共振等确定其化学和表面构成;荧光标记、荧光寿命、线粒体膜电位检测、FQ-PCR、圆二色谱等研究其肿瘤和线粒体靶向特性和作用机制;体内外实验研究其抗肿瘤效果。这种具有肿瘤细胞与线粒体双靶向性的Bcl-2蛋白抑制剂载体系统,可在透明质酸介导下靶向结合到肿瘤细胞上,进入细胞后在三苯基膦阳离子介导下靶向结合到线粒体膜上与Bcl-2蛋白作用,达到最佳Bcl-2蛋白抑制和抗肿瘤效果。

项目摘要

本项目以肿瘤细胞及其线粒体为目标靶点,综合应用棉酚及其衍生物对Bcl-2蛋白的抑制,透明质酸、三苯基膦阳离子化合物对肿瘤细胞及其线粒体的目标选择和靶向性。先将棉酚衍生物Apogossypolone (ApoG2) 用阳离子淀粉包裹成为纳米微粒,再通过交联剂EDC和N-羟基琥珀酰亚胺与三苯基膦溴代己酸阳离子的羧基结合形成线粒体靶向纳米粒子。再将PEG修饰的透明质酸包裹阿霉素形成纳米小球,最后利用静电作用将它们组装成为“桑葚’状结构的复合纳米载体,该载体具有肿瘤细胞及其线粒体双靶向载体系统。通过红外光谱、核磁共振等确定其化学和表面构成;荧光标记、荧光寿命、线粒体膜电位检测等研究其肿瘤和线粒体靶向特性和作用机制;体内外实验研究其抗肿瘤效果。这种具有肿瘤细胞与线粒体双靶向性的Bcl-2蛋白抑制剂载体系统,可在透明质酸介导下靶向结合到肿瘤细胞上,进入细胞后在三苯基膦阳离子介导下靶向结合到线粒体膜上与Bcl-2蛋白作用,达到最佳Bcl-2蛋白抑制和抗肿瘤效果。

项目成果
{{index+1}}

{{i.achievement_title}}

{{i.achievement_title}}

DOI:{{i.doi}}
发表时间:{{i.publish_year}}

暂无此项成果

数据更新时间:2023-05-31

其他相关文献

1

Efficient photocatalytic degradation of organic dyes and reaction mechanism with Ag2CO3/Bi2O2CO3 photocatalyst under visible light irradiation

Efficient photocatalytic degradation of organic dyes and reaction mechanism with Ag2CO3/Bi2O2CO3 photocatalyst under visible light irradiation

DOI:
发表时间:2016
2

Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling

Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling

DOI:10.1016/j.intimp.2021.107374
发表时间:2021
3

An alternative conformation of human TrpRS suggests a role of zinc in activating non-enzymatic function

An alternative conformation of human TrpRS suggests a role of zinc in activating non-enzymatic function

DOI:10.1080/15476286.2017.1377868.
发表时间:2017
4

Baicalin provides neuroprotection in traumatic brain injury mice model through Akt/Nrf2 pathway

Baicalin provides neuroprotection in traumatic brain injury mice model through Akt/Nrf2 pathway

DOI:10.2147/DDDT.S163951
发表时间:2018
5

IRE1-RACK1 axis orchestrates ER stress preconditioning-elicited cytoprotection from ischemia/reperfusion injury in liver

IRE1-RACK1 axis orchestrates ER stress preconditioning-elicited cytoprotection from ischemia/reperfusion injury in liver

DOI:
发表时间:2016

相似国自然基金

1

靶向Bcl-2蛋白家族抗肿瘤活性有机小分子抑制剂的优化和研究

批准号:81172984
批准年份:2011
负责人:王任小
学科分类:H3407
资助金额:68.00
项目类别:面上项目
2

靶向肿瘤干细胞的纤毛蛋白修饰腺病毒载体的研究

批准号:30600600
批准年份:2006
负责人:王星华
学科分类:H1810
资助金额:23.00
项目类别:青年科学基金项目
3

双靶向糖肽类抗肝肿瘤药物载体的设计合成

批准号:21462045
批准年份:2014
负责人:田熙哲
学科分类:B0706
资助金额:53.00
项目类别:地区科学基金项目
4

成纤维细胞激活蛋白响应的肿瘤及肿瘤微环境双靶向给药系统的研究

批准号:81603045
批准年份:2016
负责人:张全
学科分类:H3408
资助金额:17.00
项目类别:青年科学基金项目